Skip to Content

Fresenius Medical Care AG & Co. KGaA FME Stock Quote

| Rating as of


Last close prices updated as of Feb 06, 2023, 4:58 PM CET | EUR
  • Last Close 35.61
  • Sector Healthcare
  • Industry Medical Care Facilities
  • Investment Style Mid Value
  • Day Range 35.03  –  36.19
  • Year Range 26.19  –  63.66
  • Market Cap 10.5042 Bil
  • Volume / Avg 494,672.0 /  626,784.4
  • Price / Sales 0.55
  • Price / Book 0.69
  • Forward Div Yield 3.79%
  • Trailing Div Yield 2.23%

Morningstar‘s Stock Analysis FME

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Unprecedented Times Are Testing Fresenius Medical Care

Julie Utterback Senior Equity Analyst

Business Strategy and Outlook

| Julie Utterback |

Fresenius Medical Care treats end-stage renal disease patients through its dialysis clinic network, medical technology, and care coordination activities. Its strengths in these related areas help Fresenius maintain the leading global position in this market. After pandemic conditions recede, we expect the company to benefit from solid demand in developed markets, such as the U.S., and even faster expansion in emerging markets, such as China, in the long run. With global ESRD patient growth expected to remain in the low to mid-single digits in the long run, we expect top-line growth for Fresenius to be toward the top of that range after a very weak 2021 with similar earnings growth compounded annually during the next five years, if it can get past current inflationary and other challenges.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics FME

Company Profile FME

Business Description

Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of September 2021. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Else-Kroener-Strasse 1
Bad Homburg, HE, 61352, DEU
Industry Medical Care Facilities
Employees 122,758

Related Articles FME

FAQs for Fresenius Medical Care AG & Co. KGaA Stock

Yes. FME has a forward dividend yield of 3.79%. See FME’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

FME’s market cap is 10.50 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

FME’s stock style is Mid Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

FME’s price/sales is 0.55.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

FME’s price/forward earnings is 11.48.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

FME’s price/book is 0.69.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See FME’s valuation ratios compared to the Market Index.

FME’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare FME’s historical performance against its industry peers and the overall market.